Transcription of COVID-19 vaccine safety update
{{id}} {{{paragraph}}}
Example: marketing
COVID-19 vaccine safety update
National Center for Immunization & Respiratory DiseasesCOVID-19 vaccine safety updateAdvisory Committee on Immunization Practices (ACIP)March 1, 2021 Tom Shimabukuro, MD, MPH, MBACDC COVID-19 vaccine Task Force vaccine safety Team2 Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC) or the Food and Drug Administration (FDA).Mention of a product or company name is for identification purposes only and does not constitute endorsement by CDC or V-safe updateVaccine Adverse Event Reporting System (VAERS) updateVaccine safety Datalink (VSD) updateClinical Immunization safety Assessment (CISA) Project updateCOVID-19 vaccine safety in pregnancy451.
Anaphylaxis following mRNA COVID-19 vaccines Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021 Feb 12. doi: 10.1001/jama.2021.1967. Epub ahead of print. Pfizer-BioNTech. Moderna. 14. VSD.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: